Breaking News, Collaborations & Alliances

Terumo BCT, Taiwan Bio to Advance Treg Manufacturing onto Automated Platform

The collaboration leverages the 2025 Nobel Prize-winning discovery of Tregs, which regulate immune tolerance.

Author Image

By: Patrick Lavery

Content Marketing Editor

Terumo Blood and Cell Technologies (Terumo BCT) is partnering with Taiwan Bio to automate regulatory T-cell (Treg) manufacturing. The transition onto Terumo BCT’s Quantum Flex platform allows Taiwan Bio to leverage the 2025 Nobel Prize-winning discovery of Tregs. These regulate immune tolerance and are being used in the development of the therapy TRK-001, now in Phase II trials. Regarding TRK-001, its intended purpose is to prevent graft rejection in kidney transplantation. Adopting an aut...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters